Altered IgG fucosylation driving pathologies in COVID-19: Relevance for diagnosis and therapeutics
- Funded by Netherlands Organisation for Health Research and Development (ZonMW)
- Total publications:0 publications
Grant number: 1.043E+13
Grant search
Key facts
Disease
COVID-19Start & end year
20202023Funder
Netherlands Organisation for Health Research and Development (ZonMW)Principal Investigator
G VidarssonResearch Location
N/ALead Research Institution
Universitair Medisch Centrum UtrechtResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Immunity
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
People who become infected with COVID-19 have very diverse reactions. Some people don't notice anything, others show mild complaints and some become seriously ill. Typically, people with complaints either recover or experience a worsening of complaints after about a week after infection. This is accompanied by the activation of the adaptive immune system, which is then able to clear the virus. Unfortunately, this immune activation appears to be too intense in some patients. The cause of this is unclear. Research and expected outcomes Research indicates that an important functional switch in antibodies - the sugar fucose - is 'on' in some viral infections, including in seriously ill COVID-19 patients, and not in people with mild complaints. In this project, the development of this type of response and the influence on antibody (plasma) therapies in patients is studied. The results will hopefully lead to more efficient and safer use of antibody-based therapies.